Gilead’s $610M Volume and Strategic HIV Diversification Secure Market Position Amid 175th Rank

On September 9, 2025, , ranking 175th in market activity. The company detailed its strategic priorities during a presentation at the Morgan Stanley Healthcare Conference, emphasizing diversification of its HIV portfolio through lenacapavir-based programs ahead of Biktarvy’s 2033 patent expiry. , , . The firm also addressed Medicaid policy risks with state-specific mitigation strategies and underscored a strong balance sheet with no major patent expirations until 2033.

. The lenacapavir program, with its multi-frequency treatment options, positions the company to maintain market leadership in PrEP. Oncology advancements, including cell therapy milestones, . However, near-term challenges remain in navigating Medicaid reforms and ensuring lenacapavir’s broad formulary access. .

. . , , . Alternative approaches include narrowing the scope to a single index or leveraging external tools for custom scripting.